Malignant pleural mesothelioma (MPM) is a rapidly fatal malignancy with a median survival time of \< 1 year. The single most important risk factor for MPM is exposure to asbestos, which occurs in ≥ 70--80% of these patients ([@b28-ehp0116-000723]; [@b30-ehp0116-000723]). More than 3,000 deaths can be attributed to MPM each year in the United States, and worldwide its incidence is on the rise ([@b19-ehp0116-000723]; [@b23-ehp0116-000723]; [@b25-ehp0116-000723]; [@b26-ehp0116-000723]; [@b29-ehp0116-000723]). As a result of the profound disease risk associated with exposure to asbestos and the occupational setting where exposure often occurs, litigation related to asbestos disease---estimated at \$265 billion over the next 40 years---has become a tremendous economic burden ([@b2-ehp0116-000723]). Although MPM incidence trends may plateau and begin to decline in the coming years in the United States ([@b25-ehp0116-000723]; [@b26-ehp0116-000723]), asbestos-containing products are still imported into the country. Moreover, asbestos use in other nations remains widespread and significant ([@b28-ehp0116-000723]).

Following diagnosis of MPM, the options for treatment are in part dictated by known prognostic factors. Notable predictors of reduced survival in this disease are male sex and nonepithelioid histologies ([@b31-ehp0116-000723]). Recently, [@b11-ehp0116-000723] reported that a history of asbestos exposure is associated with reduced survival. In an effort to confirm and extend this observation, we used both self-reported (*n* = 128) and quantitative asbestos burden measures (*n* = 80) in a subset of cases to examine the relationship between asbestos exposure and MPM treatment outcome.

Materials and Methods
=====================

Study population and exposure data
----------------------------------

Lung tissue and tumor tissue were obtained following surgical resection of pleural mesothelioma from incident cases seen at the International Mesothelioma Program at Brigham and Women's Hospital during 2000--2006. All patients provided written informed consent under the approval of the appropriate institutional review boards.

Clinical information was obtained from review of each patients' medical record. Pathologic diagnosis and date of diagnosis were obtained from the medical record of the initial diagnosis, either at Brigham and Women's Hospital or the primary referring clinic, after having been confirmed by a pathologist's review (J.G.G.). Each patient (*n* = 128) was assessed for history of exposure to asbestos by a trained industrial hygienist (83 cases had available asbestos body burden data), and additional demographic and environmental data on medical and occupational history was obtained through an in-person questionnaire or interview. Patients were followed up for survival using the National Death Index ([@b20-ehp0116-000723]) to determine date of death. Surviving patients were censored (*n* = 48) based on their last known clinic visit.

We quantified asbestos bodies (ABs) in samples of lung tissue from multiple sites in the resected lung ([@b7-ehp0116-000723]); ABs per gram of lung (wet weight) were calculated as previously described ([@b5-ehp0116-000723]).

Statistical analysis
--------------------

We performed univariate tests for association between asbestos exposure, asbestos body burden, patient demographic, and tumor characteristic data using SAS software (SAS Institute Inc., Cary, NC). Similarly, tests for association between these variables and survival were carried out with log-rank tests on Kaplan-Meier survival probability plot strata. Also, we used a Cox proportional hazards model to adjust for covariates when examining overall patient survival.

Results
=======

We obtained tumor and lung tissue from patients during surgical resection, and although surgically treated patients tend to be slightly younger and have more epithelioid disease compared to the total MPM patient population, this cohort is highly similar to other surgically treated cohorts ([@b22-ehp0116-000723]). Survival data were available on all 128 cases; of these, 83 cases had available asbestos body burden data. Among the cases with available AB counts, three had extremely high counts---14,870, 19,681, and 303,852 ABs per gram of wet weight lung (ABs/g lung)---compared to the median count of 158. To avoid an analysis anchored by extreme values, we did not include data from these three patients.

In [Table 1](#t1-ehp0116-000723){ref-type="table"}, we present exposure, demographic, and tumor histology data for all 128 cases and for the subset of 80 cases with asbestos burden data. Cases with asbestos burden data did not differ significantly from cases without fiber burden data.

"Survival time" was defined as the time from diagnosis to death or last known follow-up. [Figure 1](#f1-ehp0116-000723){ref-type="fig"} shows the Kaplan-Meier survival probability plots stratified by sex, and the log-rank test indicates a significantly reduced survival for males compared to females (*p* \< 0.04). Similarly, [Figure 2](#f2-ehp0116-000723){ref-type="fig"} shows the Kaplan-Meier survival plots by tumor histology. These data reveal a significant difference in survival between patients with epithelioid and nonepithelioid histologies (log-rank *p* \< 0.02), as well as a significant difference among epithelioid, biphasic, and sarcomatoid histologies (log-rank *p* \< 0.01).

We then examined the relationships among asbestos exposure, asbestos fiber burden, patient demographics, tumor histology, and survival data, and we found a significant difference among asbestos fiber burden levels and survival. Among all 128 cases, self-reported exposure to asbestos was not predictive of survival in MPM (log-rank *p* = 0.44; data not shown). However, we observed a significant association between self-reported asbestos exposure and older age at diagnosis (reported exposure, 62.0 ± 9.5 years; no reported exposure, 56.9 ± 9.7 years; *t*-test, *p* \< 0.05), as well as between male sex and reported asbestos exposure (Fisher's, *p* \< 0.0001; data not shown). Quantitative asbestos burden data from 80 cases showed that males (median count, 219 ABs/g lung; range*,* 0--6,211) had significantly higher asbestos burden than females (median count*,* 20 ABs/g lung; range*,* 0--2,437; Wilcoxon *p* \< 0.0001). Models of survival by asbestos exposure did not demonstrate a linear trend; thus, data were stratified into tertiles for subsequent analysis. After stratifying asbestos burden data into tertiles of low burden (0--99 ABs/g lung), moderate burden (100--1,099 ABs/g lung), and high burden (\> 1,099 ABs/g lung), we found an association of fiber burden with survival among these groups that approached statistical significance ([Figure 3](#f3-ehp0116-000723){ref-type="fig"}; log-rank *p* = 0.06). Using a Cox proportional hazards model to adjust for covariates, cases with low asbestos fiber burden had a 3-fold elevated risk of death \[95% confidence interval (CI), 0.95--9.5; *p* = 0.06\] compared to cases with moderate burden ([Table 2](#t2-ehp0116-000723){ref-type="table"}). Patients with high asbestos fiber burden had 4.8-fold elevated risk of death (95% CI, 1.5--15.0; *p* \< 0.01) compared to patients with moderate burden ([Table 2](#t2-ehp0116-000723){ref-type="table"}). Including the three cases with extreme outlying asbestos counts in this model did not significantly alter the results (data not shown).

Discussion
==========

In this study we evaluated the relationships among asbestos exposure, asbestos fiber burden, patient demographics, tumor histology, and survival in MPM. Similar to other groups, we found that male sex and nonepithelioid histologies predict reduced survival ([@b11-ehp0116-000723]). Interestingly, we also demonstrated that after correcting for covariates, low or high lung tissue asbestos burden predicted a higher risk of death compared to moderate asbestos burden.

Historically, most asbestos exposure is occupationally related and affects individuals who mined, manufactured, or applied asbestos-containing products ([@b18-ehp0116-000723]). Given that men are more likely to be employed in asbestos-associated occupations, it is not surprising that they have higher levels of fiber burden and that the ratio of men to women with MPM is between 3:1 and 5:1 ([@b31-ehp0116-000723]). Our case series follows this pattern: Men with MPM have a significantly higher lung tissue asbestos burden and outnumber women more than three to one. Men have both higher fiber burdens and significantly reduced survival compared to women, making it reasonable to posit that an increased asbestos fiber burden may contribute to poor survival per se. Consistent with this, we observed an increased risk of death among patients with high asbestos burden compared to patients with moderate asbestos burden. However, we also found an increased risk of death among patients with the lowest lung tissue asbestos burden versus those with moderate fiber burden.

The mechanism responsible for this unusual dose--response association with survival is unclear. One possibility is that cases with low asbestos burden were exposed to chrysotile asbestos or other naturally occurring mineral fibers, such as erionite, that have been associated with MPM ([@b4-ehp0116-000723]). Chrysotile asbestos is less biopersistent and is considered by many to be less pathogenic than amphibole asbestos. Hence, significant exposure to chrysotile could have occurred in those with lower numbers of ABs, and this might not be evident in our data. However, lung chrysotile fiber burden has been shown to correlate with asbestos body levels, arguing against significant chrysotile exposure ([@b3-ehp0116-000723]).

Concomitantly, erionite fibers are reported to have the highest carcinogenic potential of studied fibers, and form ferruginous bodies indistinguishable from ABs ([@b10-ehp0116-000723]). Because erionite fibers do not form ferruginous bodies as readily as asbestos fibers, the AB counts in individuals with erionite exposure may underestimate their true internal dose ([@b10-ehp0116-000723]). The worldwide geographic distribution of erionite is very limited; therefore, it is unlikely that patients in this study had this exposure. However, if either of these scenarios were true (patients with low AB counts having significant chrysotile or erionite exposure), it would imply that the fiber dose is directly associated with survival.

A more likely explanation of our results is related to the considerable literature that has documented both the absence of an appreciable threshold for asbestos-induced mesothelioma, and the fact that MPM can occur with very low-level exposures ([@b13-ehp0116-000723]; [@b14-ehp0116-000723]). Further, widespread exposures to asbestos, particularly environmental exposures in some parts of the world, combined with the rare incidence of mesothelioma, suggest that there may be susceptible individuals. In fact, multiple reports indicate that genetics may modify susceptibility to MPM ([@b1-ehp0116-000723]; [@b6-ehp0116-000723]; [@b9-ehp0116-000723]; [@b12-ehp0116-000723]; [@b15-ehp0116-000723]; [@b16-ehp0116-000723]; [@b17-ehp0116-000723]; [@b21-ehp0116-000723]; [@b24-ehp0116-000723]; [@b27-ehp0116-000723]). When closely examining our asbestos fiber burden data, we found that most of the cases within the low-asbestos-burden group (0--99 ABs/g lung) had AB counts within the general population mean of 0--20 ABs/g lung ([@b8-ehp0116-000723]); thus these patients may have a greater inherent susceptibility. Further, our data lead to the hypothesis that patients with high susceptibility suffer from more aggressive disease. Outside this high susceptibility group, the other two tertiles demonstrated a dose--response relationship between asbestos fiber burden and survival.

In summary, our data suggest that patient survival is associated with asbestos fiber burden in pleural mesothelioma and that this association is perhaps modified by susceptibility. Studies using larger case groups---ideally with chrysotile and erionite exposure data---are necessary to further elucidate the ability of asbestos burden to predict survival in MPM.

This study was supported by a research grant from the International Mesothelioma Program at Brigham and Women's Hospital, a grant from the Mesothelioma Applied Research Foundation, two grants from the National Institutes of Health/ National Institute of Environmental Health Sciences (NIH/NIEHS; training grant T32ES007155 and grant P42ES05947), and grant CA126939 from the National Cancer Institute.

![Kaplan-Meier survival probability plots of MPM patients (*n* = 128) by sex, using the log-rank method to test for a difference between strata. Males (*n* = 98) had significantly reduced survival compared to females (*n* = 30; *p* \< 0.04). Surviving patients (*n* = 48) were censored.](ehp0116-000723f1){#f1-ehp0116-000723}

![Kaplan-Meier survival probability plots of MPM patients (*n* = 128) based on tumor histology, using the log-rank method to test for a difference between strata. (*A*) Survival of patients with an epithelioid tumor (*n* = 91) and those with a mixed or sarcomatoid tumor (*n* = 37); patients with a nonepithelioid tumor had significantly reduced survival compared to those with an epithelioid tumor (*p* \< 0.02; *n* = 128). (*B*) Survival of patients with an epithelioid (*n* = 91), biphasic (*n* = 33), or sarcomatoid tumor (*n* = 4); survival was significantly different among patients with the three tumor types (*p* \< 0.01). Surviving patients (*n* = 48) were censored.](ehp0116-000723f2){#f2-ehp0116-000723}

![Kaplan-Meier survival probability plots of MPM patients based on asbestos burden, using the log-rank method to test for a difference among strata. Survival differences among exposure groups approaches statistical significance (*p* = 0.06). Eighty patients had AB counts; surviving patients (*n* = 48) were censored.](ehp0116-000723f3){#f3-ehp0116-000723}

###### 

Demographics and tumor characteristics of mesothelioma patients.

  Characteristic                                                        Total (*n* = 128)   Asbestos burden data (*n* = 80)
  --------------------------------------------------------------------- ------------------- ---------------------------------
  Sex                                                                                       
   Female                                                               30 (23)             20 (25)
   Male                                                                 98 (77)             60 (75)
  Age (years)                                                                               
   Range                                                                30--85              30--80
   Mean ± SD                                                            62 ± 10.1           61 ± 9.8
  Histology                                                                                 
   Epithelioid                                                          91 (71)             60 (75)
   Mixed                                                                33 (26)             18 (22.5)
   Sarcomatoid                                                          4 (3)               2 (2.5)
  Asbestos exposure[a](#tfn2-ehp0116-000723){ref-type="table-fn"}                           
   Yes                                                                  95 (74)             59 (74)
   No                                                                   33 (26)             21 (26)
  AB count (ABs/g lung)[b](#tfn3-ehp0116-000723){ref-type="table-fn"}                       
   Range (median)                                                       NA                  0--6,211 (128)
   Mean ± SD                                                            NA                  875 ± 1,467

NA, not applicable. Values are number (%) except where indicated.

Self-reported.

Data for 83 cases available; three outliers removed.

###### 

Asbestos body burden predicts survival in MPM, Cox's proportional hazards model.

  Covariate               No. (%)   Hazard ratio (95% CI)   *p*-Value
  ----------------------- --------- ----------------------- -----------
  Sex                                                       
   Male                   60 (75)   1.0 (reference)         
   Female                 20 (25)   0.72 (0.27--1.9)        0.94
  Histology                                                 
   Epithelioid            54 (77)   1.0 (reference)         
   Mixed                  14 (20)   0.82 (0.38--1.8)        0.62
   Sarcomatoid            2 (3)     3.7 (0.35--39.1)        0.28
  AB count (ABs/g lung)                                     
   0--99                  37 (46)   3.0 (0.95--9.5)         0.06
   100--1,099             21 (26)   1.0 (reference)         
   \> 1,099               22 (28)   4.8 (1.5--15.0)         \<0.01

The model controlled for age and all variables shown.
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